Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Depreciation and Depletion (2022 - 2023)

Candel Therapeutics' Depreciation and Depletion history spans 2 years, with the latest figure at $300000.0 for Q4 2023.

  • For Q4 2023, Depreciation and Depletion rose 35.75% year-over-year to $300000.0; the TTM value through Dec 2023 reached $1.0 million, changed N/A, while the annual FY2024 figure was $990000.0, 1.0% down from the prior year.
  • Depreciation and Depletion for Q4 2023 was $300000.0 at Candel Therapeutics, up from $200000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $300000.0 in Q4 2023 and bottomed at $200000.0 in Q3 2023.